CANCER CROSSLINKS 2024
Bridging innovations to improve clinical outcomes for cancer patients.
The 16th Cancer Crosslinks was presented on
Thursday, January 25, 2024
Daytime Educational Program 10:00 - 16:15 // Afternoon Networking Session from 16:15
The event was held on-site at Oslo Cancer Cluster Innovation Park with a digital option.
Location: Ullernchausseen 64, Oslo, Norway.
Distinguished speakers from Germany, France, UK & USA addressed emerging diagnostic and treatment options for solid and hematological cancers.
The event was held on-site at Oslo Cancer Cluster Innovation Park with a digital option.
Location: Ullernchausseen 64, Oslo, Norway.
Distinguished speakers from Germany, France, UK & USA addressed emerging diagnostic and treatment options for solid and hematological cancers.
Event 2024 - International Speakers
Sonja Loges, Professor, Director, DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Dept of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), German Center for Lung Research (DZL), Heidelberg, Germany
Lisa Derosa, Immuno-Oncologist, Associate Professor, Clinical Director of Clinicobiome, The Microbiome Clinic, U1015 Tumour Immunology and Anti-Cancer Immunotherapy Unit, Institut Gustave Roussy, Paris, France.
Leo Rasche, Senior Physician, Specialist in Internal Medicine, Haematology and Oncology, University Hospital Würzburg, Junior Group Leader, Mildred Scheel Nachwuchszentrum (MSNZ) for Cancer Research, Germany.
Raza Ali, Group Leader, Systems Cancer Pathology Lab, Honorary Consultant Pathologist, Cancer Research UK Cambridge Institute, University of Cambridge, UK.
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mihaela van der Schaar, John Humphrey Plummer Professor of Machine Learning, AI, and Medicine. Director, Cambridge Center for AI in Medicine, University of Cambridge, UK.
Event 2024 - Topics
SESSION 1 - EXPLORING THE FUTURE OF CANCER IMMUNOTHERAPY
Opening keynote address
Personalized Oncology - recent progress and path to the future
Sonja Loges, German Cancer Research Center (DKFZ), Heidelberg, Germany
Personalized Oncology - recent progress and path to the future
Sonja Loges, German Cancer Research Center (DKFZ), Heidelberg, Germany
Microbiota-centered interventions and cancer immunotherapy: recent learnings and
clinical implications
Lisa Derosa, Institut Gustave Roussy, Paris, France.
clinical implications
Lisa Derosa, Institut Gustave Roussy, Paris, France.
SESSION 2 – IMPACTS ON CLINICAL OUTCOMES BY TARGETING TUMOR HETEROGENEITY
Tumor heterogeneity in multiple myeloma: clinical consequences?
Leo Rasche, University Hospital Würzburg,
Mildred Scheel Nachwuchszentrum (MSNZ) for Cancer Research, Germany.
Leo Rasche, University Hospital Würzburg,
Mildred Scheel Nachwuchszentrum (MSNZ) for Cancer Research, Germany.
Highly multiplexed imaging for precision breast immuno-oncology
Raza Ali, Cancer Research UK Cambridge Institute, University of Cambridge, UK.
Raza Ali, Cancer Research UK Cambridge Institute, University of Cambridge, UK.
SESSION 3 - EMERGING PLATFORMS FOR CANCER TREATMENT DELIVERY
Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer
Paolo Tarantino, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Paolo Tarantino, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Revolutionizing Oncology: AI-Driven Innovations on Cancer Pathways
Mihaela van der Schaar, Cambridge Center for AI in Medicine, University of Cambridge, UK.
Mihaela van der Schaar, Cambridge Center for AI in Medicine, University of Cambridge, UK.
Event 2024 - Moderators from Norway
Moderators:
Vilde Drageset Haakensen, Senior Consultant Oncologist and Head of Lung Cancer Research, Dept. of Oncology & Project group leader, Dept of Cancer Genetics, Oslo University Hospital, Norway.
Marte Grønlie Cameron, Clinical Oncologist, Palliative Care Unit and Head of Research at the
Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway.
Fredrik Schjesvold, Leader of Oslo Myeloma Center, Dept. of Haematology, Oslo University Hospital, Norway. Head of the Norwegian Myeloma Association, President of the Nordic Myeloma Study Group and board member of the European Myeloma Network.
Katrin Kleinmanns, Researcher, Center for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway.
Event 2024 - Travel Voucher
A limited number of travel vouchers were available for clinicians and healthcare personnel based in Norway (domestic travel, first come, first served).
Event 2024 - Reference Materials
Vilde Drageset Haakensen, Senior Consultant Oncologist and Head of Lung Cancer Research, Dept. of Oncology & Project group leader, Dept of Cancer Genetics, Oslo University Hospital, Norway.
Marte Grønlie Cameron, Clinical Oncologist, Palliative Care Unit and Head of Research at the
Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway.
Fredrik Schjesvold, Leader of Oslo Myeloma Center, Dept. of Haematology, Oslo University Hospital, Norway. Head of the Norwegian Myeloma Association, President of the Nordic Myeloma Study Group and board member of the European Myeloma Network.
Katrin Kleinmanns, Researcher, Center for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway.
Event 2024 - Travel Voucher
A limited number of travel vouchers were available for clinicians and healthcare personnel based in Norway (domestic travel, first come, first served).
Event 2024 - Reference Materials
|
Organizer
|
Sponsors 2024
|
|
|
|
To learn more about previous Cancer Crosslinks events, visit the GALLERY.